These data demonstrate that serum levels of the human monoclonal Igs and AKAP-4 can be used to monitor MM progression in vivo in murine models and aid in the pre-clinical evaluation of new anti-myeloma therapies. This evidence concerns the gene AKAP4 and Miyoshi myopathy.